DJIA 18,080.14 21.45 0.12%
NASDAQ 5,092.09 36.02 0.71%
S&P 500 2,117.69 4.76 0.23%
market minute promo

Horizon Pharma, Inc. (NASDAQ: HZNP)

31.75 0.97 (3.15%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

HZNP $31.75 3.15%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $30.80
Previous Close $30.78
Daily Range $30.78 - $31.78
52-Week Range $7.85 - $32.15
Market Cap $4.0B
P/E Ratio -9.77
Dividend (Yield) $0.00 (0.0%)
Volume 6,280,176
Average Daily Volume 4,424,728
Current FY EPS $1.39

Sector

Healthcare

Industry

Drug Makers

Horizon Pharma, Inc. (HZNP) Description

Horizon Pharma Inc is a biopharmaceutical company that is developing and commercializing innovative medicines to target unmet therapeutic needs in arthritis pain and inflammatory diseases. Website: http://www.horizonpharma.com/

News & Commentary

3 Top Healthcare Stocks Surging Higher This Year

Eagle Pharmaceuticals Inc., Esperion Therapeutics Inc., and Horizon Pharma plc have more than doubled investors' money this year.

Intercept Pharmaceuticals Releases Data on Lead Drug - Analyst Blog

Acorda Reports Encouraging Data on MS Drug - Analyst Blog

Acorda Reports Encouraging Data on MS Drug - Analyst Blog

Emergent BioSolutions Resumes BioThrax Manufacturing - Analyst Blog

Pfizer's Cancer Drug Meets First Primary Endpoint in Phase III - Analyst Blog

Actelion (ALIOF) Beats Q1 Earnings & Revenue Expectations - Analyst Blog

Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice o

Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering RAYOS Delayed-Release Tablets

The Medicines Co.'s New Minocin Formulation Approved - Analyst Blog

The Medicines Co.'s New Minocin Formulation Approved - Analyst Blog

Seattle Genetics' Adcetris Under Review for New Indication - Analyst Blog

Seattle Genetics' Adcetris Under Review for New Indication - Analyst Blog

Merck's Keytruda Tops Melanoma, Lung Cancer Studies - Analyst Blog

OncoMed Down on Phase Ib Lung Cancer Study Data - Analyst Blog

See More HZNP News...